Stockbroker tips from ShareCast
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
Deutsche Bank downgrades Oxford Biomedica after 'disappointing' H1 results
Tue 18 August 2026 14:32
(Sharecast News) - Deutsche Bank downgraded Oxford Biomedica to 'hold' from 'buy' on Tuesday and slashed the price target to 595p from 800p as it revisited the investment case following the "disappointing" first-half trading update.
Broker tips: Rolls Royce, Oxford Biomedica
Tue 18 August 2026 13:58
(Sharecast News) - Analysts at Berenberg lifted their target price on Rolls‑Royce to 1,900p from 1,430p, citing the group's continued outperformance in engine flying hours and its strong positioning across civil aerospace, defence and power systems.
Bernstein upgrades Whitbread to 'market perform', says 5-year plan is 'realistic'
Tue 18 August 2026 09:49
(Sharecast News) - Bernstein upgraded Whitbread on Tuesday to 'market perform' from 'underperform' and lifted the price target to 2,400p from 2,100p as it said the company's new five-year plan was "realistic" and it's time to adopt a "more constructive st
Berenberg raises target price on Rolls-Royce
Tue 18 August 2026 06:58
(Sharecast News) - Analysts at Berenberg lifted their target price on Rolls‑Royce to 1,900p from 1,430p, citing the group's continued outperformance in engine flying hours and its strong positioning across civil aerospace, defence and power systems.
RBC Capital says IG Group oversold on Underdog deal, reiterates 'outperform'
Fri 14 August 2026 09:47
(Sharecast News) - RBC Capital Markets reiterated its 'outperform' rating on IG Group on Friday as it argued the stock was oversold on news of the acquisition of US prediction markets operator Underdog.
Berenberg raises Gym Group target price, cites multi‑year growth potential
Fri 14 August 2026 08:21
(Sharecast News) - Analysts at Berenberg hiked their target price for The Gym Group from 255p to 295p on Friday, saying the low‑cost operator offered a multi‑year growth story in an underpenetrated market and remains attractively valued.